readthroughSign in
Jun 30, 2026Trial update4 fact check notes

Annexon posts results for ANX005 Phase 2 wAIHA study, completed with 7 participants

Annexon's Phase 2 trial of ANX005 in warm autoimmune hemolytic anemia has reported results after completing with a small enrolled cohort.

  • ANX005, an intravenous complement C1q inhibitor, was tested in a Phase 2, open-label study in participants with warm autoimmune hemolytic anemia (wAIHA), sponsored by Annexon, Inc. The study is listed as completed, with an actual start date of 2021-11-10 and primary completion on 2023-01-171. Results were first posted on 2026-06-301. Actual enrollment was 7 participants1. The design called for two once-weekly intravenous infusions of ANX0051, with the primary safety outcome tracking treatment-emergent adverse events from Day 1 through Day 711.

Fact check notes

  • ImpreciseANX005 is an intravenous complement C1q inhibitorThe source doesn't explicitly describe ANX005's mechanism as a 'C1q inhibitor'; this is inferred from keywords and outcome measures tracking C1q levels rather than stated directly.
  • Checker's noteThe phrase 'this week' is not supported by any date in the source and appears to be an added framing claim.
  • Checker's noteDescribing ANX005 explicitly as a 'C1q inhibitor' is an inference from keywords/outcome measures rather than an explicit statement in the source.
  • Sentence removedAnnexon's registry update this week centers on a completed Phase 2 study of its complement inhibitor in a rare blood disorder.unsupported: No information in the source indicates the timing of this reporting relative to 'this week'; this appears to be an unsupported framing detail added by the entry.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.